PropThink
PropThink
Stop FollowingPropThink
ABOUT
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital ...More requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital ...More requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
SNAPSHOT
- Description: Independent / boutique research firm analyst. Trading frequency: Daily
- Interests: Options, Stocks - long, Stocks - short
COMPANY
PropThink PropThink is the leading online destination for retail and institutional investors seeking actionable analysis of publicly-traded, emerging growth companies in the healthcare sector. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully ...More
commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
BLOG
Book
Currently, there are no book details for PropThink.
Latest Comments
more »
- Agree to an extent Shane, b... on Synergy Is A Straightforward Opportunity: Trial...
- Reimbursement is purely for... on Value Investors Take Note: Fire Sale On This He...
- "Time will tell if Mak... on MAKO Surgical: Burden Of Proof Still On Management
- Dr. Chaudhry's post-vote as... on Aveo's Inflection Point: Tivozanib Likely To Re...
- If we could find shares to ... on Zogenix Poised For 40% Haircut As Zohydro Decis...
Latest comments on PropThink's Articles
- Shane Blackmon on Synergy Is A Straightforward Opportunity: Trial...
- PropThink on Synergy Is A Straightforward Opportunity: Trial...
- Shane Blackmon on Synergy Is A Straightforward Opportunity: Trial...
- Michael44 on Synergy Is A Straightforward Opportunity: Trial...
- Shane Blackmon on Synergy Is A Straightforward Opportunity: Trial...
Latest Articles on Healthcare
LATEST ARTICLES & INSTAPOSTS
more »
- Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide
- Value Investors Take Note: Fire Sale On This Heart Failure Asset
- An FDA Meeting Becomes New Focus For Titan Pharma
- Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals
- Markman Hearing A Likely Clearing Event For Cubist - Decision Any Day


